Skip to main content

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

Recruiting · Phase 1 · NCT07024641

Conditions: Hepatitis B Virus Infection

At a glance

Research payments reported, 2025
$245,283
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
48

About the trial

Sponsor
GigaGen, Inc.
Tested
GIGA-2339 (drug), Placebo (drug)
Dates
Started 2024-11-13; completion 2028-11
Results posted
Not yet

The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.

From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Grifols Shared Services North America, Inc. reported $245,283 in research payments for this study in 2025 (51 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • American Research Corporation $63,257
  • University of Iowa Hospital & Clinics, IA $33,898
  • Virginia Commonwealth University Office of Sponsored Programs $33,160
  • The Institute of Liver Health II LLC dba Arizona Clinical Trials $26,653
  • Memorial Research Medical Clinic DBA Orange County Research Center $20,645
  • Long Beach Center for Clinical Research $17,000
  • Tranquil Clinical Research $15,780
  • The Oakland Institute of Health, Inc $15,750
  • Marvel Clinical Research, Llc $14,900
  • Massachusetts General Hospital, MA $4,240

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.